Pharma
Fredun Pharmaceuticals Ltd
FREDUN · BSE ·Thursday, 10 Sept 2026Vol: 9.7K traded · 57.9% delivered9:42 am
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE15.6%
ROCE21.3%
ROE15.6%
1Y Return+84.98%
Avg. Volume0.0M
Delivery %57.93%
Price Chart
52-Week Range
About
Fredun Pharmaceuticals Ltd is a Pharma company listed on BSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹1,473
52W High / Low₹1,599.9 / ₹390.57
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE15.6%
1Y Return+84.98%
Day Change+2.62%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|---|
| Sales | ₹748 Cr | ₹635 Cr | ₹454 Cr | ||
| Expenses | ₹637 Cr | ₹545 Cr | ₹401 Cr | ||
| Operating Profit | ₹110 Cr | ₹91 Cr | ₹52 Cr | ||
| OPM % | 15.0% | 14.0% | 12.0% | ||
| Other Income | ₹0 Cr | ₹4 Cr | ₹2 Cr | ||
| Depreciation | ₹10 Cr | ₹8 Cr | ₹5 Cr | ||
| Interest | ₹41 Cr | ₹39 Cr | ₹22 Cr | ||
| Profit Before Tax | ₹59 Cr | ₹47 Cr | ₹27 Cr | ||
| Tax | ₹15 Cr | ₹14 Cr | ₹7 Cr | ||
| Net Profit | ₹44 Cr | ₹33 Cr | ₹20 Cr | ||
| EPS (₹) | 27.7 | 19.9 | 13.9 | ||
| Dividend Payout % | — | 1% | 2% |
Financial history locked
Register freeRegister free to see 2 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
|---|---|---|---|---|---|---|---|
| Sales | ₹228 Cr | ₹213 Cr | ₹161 Cr | ₹145 Cr | |||
| Expenses | ₹196 Cr | ₹184 Cr | ₹135 Cr | ₹123 Cr | |||
| Operating Profit | ₹33 Cr | ₹29 Cr | ₹26 Cr | ₹22 Cr | |||
| OPM % | 14.0% | 14.0% | 16.0% | 15.0% | |||
| Depreciation | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | |||
| Interest | ₹9 Cr | ₹14 Cr | ₹11 Cr | ₹8 Cr | |||
| Net Profit | ₹13 Cr | ₹11 Cr | ₹10 Cr | ₹9 Cr | |||
| EPS (₹) | 8.0 | 6.6 | 6.5 | 6.6 |
Quarterly history locked
Register freeRegister free to see 3 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹5 Cr | ₹5 Cr | ₹5 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹273 Cr | ₹137 Cr | ₹117 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹222 Cr | ₹167 Cr | ₹106 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹142 Cr | ₹178 Cr | ₹81 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹642 Cr | ₹487 Cr | ₹308 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹118 Cr | ₹53 Cr | ₹48 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹2 Cr | ₹2 Cr | ₹1 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | ₹65 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | ₹175 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | ₹1 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹522 Cr | ₹433 Cr | ₹18 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹642 Cr | ₹487 Cr | ₹308 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 2 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹12 Cr | ₹-74 Cr | ₹121 Cr | ₹60 Cr |
| FY25 | ₹-17 Cr | ₹-6 Cr | ₹27 Cr | ₹4 Cr |
| FY24 | ₹-0 Cr | ₹-8 Cr | ₹6 Cr | ₹-2 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 2 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-08Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseBSE Filing2026-08-15Fredun Pharmaceuticals Ltd (BOM:539730) (Q1 2027) Earnings Call Highlights: Record 90% Revenue ...GuruFocus.com2026-06-12Fredun Pharmaceuticals Ltd (BOM:539730) Q4 2026 Earnings Call Highlights: Robust Growth and ...GuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.